As already mentioned, sequence variation of IDH1 is a better prognostic marker and is significantly associated with longer survival in men with GBM than in women [38,39], whereas the methylated MGMT promoter is more common and is associated with longer survival only in women [15,38,40]. This evidence concerns the gene MGMT and glioblastoma.